Context.-Experiences at our institution show that flow cytometry analysis (FCA) has become routine clinical practice in the workup of patients with altered mental status, even if risk factors are low.
with no history of lymphoma and no suspicious radiology (n ¼ 102) had negative cytology, and none had a correspondingly positive FCA result. The positive and negative predictive values of combined cytology and FCA in the patients with history of lymphoma and/or abnormal imaging results were 92% and 89%, respectively, when compared with open brain tissue biopsy, and 89% and 86%, respectively, when compared with clinical followup. When low-risk patients were included, the positive predictive value remained at 92%, but the negative predictive value dropped to 52% with the open brain biopsy as the reference, and values did not change significantly for the group with clinical follow-up.
Conclusions.-Concurrent FCA and cytology are most useful in the appropriate clinical setting, and we propose a triage algorithm for how FCA on cerebrospinal fluid is best used.
(Arch Pathol Lab Med. 2013;137:1610-1618; doi: 10.5858/arpa.2012-0313-OA) I nvolvement of the central nervous system (CNS) by lymphoma, whether primary or systemic, is uncommon but has a dismal prognosis. 1 Primary CNS lymphoma accounts for~3% of all primary CNS tumors and can involve the brain, leptomeninges, spinal cord, and eyes. 2, 3 Human immunodeficiency virus infection is an established risk factor for developing this type of lymphoma. 4 Secondary CNS involvement occurs in approximately 5% of patients with non-Hodgkin lymphoma and may present synchronously to the initial lymphoma diagnosis, as a relapse, or during the course of progressive disease. Non-Hodgkin lymphoma may involve the CNS either by forming intraparenchymal masses or, more commonly, by infiltrating the leptomeninges. 5 The incidence of secondary involvement varies with the aggressiveness of the lymphoma, and ranges from 3% for indolent lymphomas to 27% for highgrade lymphomas. 1 Given the potential side effects of intrathecal chemotherapy and CNS irradiation for CNS lymphoma, the diagnosis needs to be unequivocal. 6 Although long regarded as the gold standard for diagnosing CNS lymphoma, cytologic examination of cerebrospinal fluid (CSF) yields a low sensitivity with a false-negative rate between 20% and 60%. 1 Paucity of lymphoma cells due to small sample size, difficulties differentiating lymphoma cells from reactive CSF lymphocytes, frequent upfront use of corticosteroids in symptomatic patients, and inability to sample near the anatomic location of the lymphoma all contribute to the poor sensitivity. 7 Recent studies have shown that CSF flow cytometry greatly improves the diagnostic accuracy of CNS involvement by lymphoma, a technique that can detect clonal B cells at as low as 0.9%, compared with a sensitivity of 5% by morphology alone. [8] [9] [10] In patients with high clinical suspicion for CNS lymphoma, submission of CSF for both cytology and flow cytometry analysis (FCA) is now recommended by the National Comprehensive Cancer Network. 3 Neurologic symptoms often prompt the clinician to order multiple and simultaneous diagnostic tests to determine the etiology of CNS lymphoma in a timely manner. Consequently, at our institution, FCA of CSF has become a routine screening method in the workup of patients with altered mental status, even when CNS lymphoma ranks low on the list of potential etiologies.
Understanding that this procedure is likely considered beneficial for the patient (fewer lumbar punctures, quicker diagnosis, etc), we set out to assess the utility of flow cytometry in an unselected patient population with neurologic symptoms, including patients with no history of lymphoma or no radiologic findings. We chose to compare the findings of FCA and cytology to histology from a brain biopsy as well as to clinical follow-up, where available. Finally, we describe the most appropriate clinical circumstances that may justify simultaneous ordering of both cytology and flow cytometry over the more-traditional approach of cytology evaluation alone.
MATERIALS AND METHODS

Case Selection
The study protocol was reviewed and approved by the Institutional Review Board of Washington University (St Louis, Missouri). For this retrospective cohort study, a search of the database of the Division of Anatomic and Molecular Pathology at the Washington University School of Medicine was conducted for all CSF samples sent for FCA between June 2001 and June 2011, for which clinicians had requested a lymphoma screen. A total of 501 samples from 373 patients met the inclusion criteria. Cerebrospinal fluid samples that had been obtained during the same procedure and sent for cytologic examination were matched to the samples submitted for flow cytometry using the pathology database. Clinical and pathology records were reviewed retrospectively to collect data on patient age, medical history, radiologic imaging studies, final pathologic diagnosis, and subsequent clinical management.
Flow Cytometry and Cytology of CSF
Before July 5, 2008, flow cytometric analysis was run on a CSF sample only if the cell count was greater than 0.1 3 10 6 /lL. Instead, a Wright-Giemsa-stained cytospin was prepared for morphologic evaluation. After that date, FCA was attempted on all CSF specimens regardless of the cell count.
Specimens submitted to rule out ''lymphoma'' received a 5-color staining (FITC/PE/ECD/PC5/PC7) screening monoclonal antibody combination of sk/sj/sCD3/CD10/CD19. If the cell count was less than 0.1 3 10 6 /lL, no additional tubes were prepared for more complete immunophenotyping. With a cell count between 0.1 and 0.4 3 10 6 /lL, an additional tube, besides the screening tube, was prepared for more complete immunophenotyping. If a clonal B-cell population was detected, CD5, CD23, and CD20 were added to the panel. If a mature T-cell lymphoma or acute lymphoblastic leukemia/lymphoma was suspected, the panel could be expanded to include some of the T-cell or blast markers: CD1, CD2, CD4, CD5, CD7, CD8, CD30, CD56/CD16, TCR a/b, TCRc/d, TdT, or CD34. A cell count of 1 3 10 6 /lL or greater yielded a total of 6 tubes for flow cytometry and provided the opportunity for the mostcomplete antibody panels when indicated.
In patients with a history of lymphoma, other than mature B-cell lymphoma, the initial 5-color sk/sj/sCD3/CD10/CD19 antibody screen was foregone, and antibodies were picked according to the diagnostic immunophenotype.
In general, results of less than 100 events in the gate of interest were not reported, and the sample was regarded as having ''too few cells'' for analysis. Additionally, cases with ''too few B cells for clonality studies'' were also grouped into the too-few-cells category for the purposes of this analysis, given that a definitive negative or positive diagnosis could not be rendered.
The primary hematopathologist interpreted the flow cytometry of the CSF, as well as a Wright-Giemsa-stained cytospin prepared from any remaining CSF fluid. The cytopathologist signed out the cytology report on the corresponding sample sent to cytopathology for Diff-Quik Stain Set (Siemens Healthcare Diagnostic, Deerfield, Illinois) preparation. Cytology diagnoses were benign in origin when designated ''negative'' or ''atypical, favor benign.'' A cytology designation of ''suspicious'' implied highly worrisome for lymphoid malignancy.
Statistical Analysis
Statistical analyses were performed using SPSS (Version 20; Chicago, Illinois). For categoric variables, the v 2 test or Fisher exact test was used. For continuous variables, the Student t test or Kruskall-Wallis test was used. All the statistical analyses were 2-sided, and P .05 was considered statistically significant.
RESULTS
Patient Characteristics
From June 2001 to June 2011, 373 patients had CSF samples submitted to pathology. Characteristics of the study population are presented in Table 1 . Most of the patients presented with neurologic symptoms (78%; 291 of 373), whereas almost one-third of patients had a known history of hematologic malignancy. Brain imaging before lumbar puncture was performed in 93% (347 of 373) of the cases, and 51% (179 of 347) of those patients had abnormal imaging findings.
Flow Cytometry Results From CSF Samples
Overall, 501 CSF samples were received for immunophe- Multiple flow samples were sent on the same patient in 80 of 373 cases (21%), for a total of 208 of the 501 samples (42%). In this group, 6 of the 80 patients (8%) had at least one positive result. Three of the 6 positive diagnoses (50%) were given on the first sample. Two of the 6 positive diagnoses (33%) were on the second flow sample, each of which was submitted within 1 month of the first. In those cases, the first flow diagnosis had been ''too few cells for flow cytometry.'' One patient (17%) was given a positive flow diagnosis on the third flow sample; however, that sample was drawn 1 year after the second. Again, the initial flow diagnoses had been ''too few cells.'' Overall, of the 14 patients who had a positive flow diagnosis, 11 (79%) were diagnosed on the first flow test, whereas 3 (21%) required additional testing after the first samples had too few cells.
Roughly, 19% of CSF samples (95 of 501) submitted for flow cytometry were shown to have a polytypic B-cell population. The mean CD19:CD3 ratio (0.48) of the 21 lymphoma cases (4%) was significantly higher than the mean CD19:CD3 ratio (0.09) of the polytypic cases (P ¼ .001). None (0%) of the 25 T-cell panels revealed an overtly abnormal T-cell population.
Cytology Results From CSF Samples
Concurrent but independent cytologic evaluation by a cytopathologist was performed on 424 of 501 samples (85%) (Figure 3, A) . Of the 77 samples that underwent FCA only, 27 samples (35%) were follow-up from patients with recent flow cytometry and cytology of a CSF sample, 7 samples (9%) were from patients after intrathecal chemotherapy, and 43 samples (56%) were not sent to cytology for unspecified clinical reasons.
Thirty-five of the 424 cases (8%) were interpreted as positive or suspicious for involvement by a lymphoid malignancy ( Figure 3 , A and B; Table 2 ). Within these 35 cases, cytologic examination was able to detect 13 lymphoid malignancies (37%) that were not detected by flow cytometry (either too few cells for meaningful analysis [10 of 13 samples; 77%] or were negative for malignancy [3 of 13 samples; 23%]). Cytologic examination also provided false-positive results in 8 of the 373 patients (2%) with no history of a hematologic malignancy, whose altered mental status was due to benign causes. False-negative results occurred in 17 of 373 patients (3%); of which, 16 of the 17 (94%) had a history of lymphoma and/or abnormal radiologic findings (Table 2 ). Unlike the FCA cases, a positive cytologic diagnosis was not dependent on the patients' history or radiologic findings (P ¼ .51).
Additionally, of the 373 patients, 102 (27%), who had no history of lymphoma and no suspicious radiologic findings, had 116 negative cytology samples (23%). None (0%) of the 116 samples had a correspondingly positive flow cytometry. Only one of these patients (0.8%) was later diagnosed with a primary CNS lymphoma, and that diagnosis was made on tissue histology after 2 negative FCA, one insufficient FCA, and one negative cytology.
Brain Biopsy Results and Predictive Values
Finally, 65 of the 373 patients (17%) underwent brain biopsy, and an additional 14 patients (4%) were found to have lymphomatous involvement of the CNS that had not been detected by either FCA or cytologic examination (Table  2) .
Of the 65 patients (17%) who underwent a brain biopsy, the positive predictive value (PPV) and negative predictive value (NPV) of cytology alone were 50% and 72%, respectively. With combined cytology and flow cytometry studies, where one or both were positive, the PPV increased to 92%, but the NPV was only 52%. Patients with either a history of lymphoma and/or suspicious findings on brain imaging were more likely to have a positive FCA or brain biopsy (P , .001). When limited to this higher-risk population, the positive and negative predictive values were 92% and 89%, respectively.
Clinical Follow-up and Predictive Values
Clinical follow-up was available in 306 of the 373 patients (82%). Looking at all 306 patients, the PPV and NPV of combined cytology and flow cytometry were 79% and 89%, respectively. When limited to the higher-risk population (patients with either a history of lymphoma and/or suspicious radiologic findings) the PPV increased to 89% and the NPV remained stable at 86%. 
COMMENT
Patients with lymphoma of the CNS, whether primary or secondary, have decreased overall survival when matched to patients with extracerebral lymphoma only, even when the CNS disease has not yet manifested itself through symptoms. 7, 11 Although the numbers of patients with primary and secondary CNS lymphomas are relatively small, the poor outcome of this group rightly gives rise to research focusing on improved detection and treatment of CNS disease. 12 Flow cytometry has established itself as a valuable tool in complementing cytology in the detection of hematologic malignancies, especially in secondary CNS lymphoma, where leptomeningeal involvement is more common than parenchymal involvement and, hence, more accessible to lumbar puncture. 5 Hedge et al 9 detected occult leptomeningeal disease by flow cytometry in 11 of the 51 newly diagnosed, aggressive B-cell lymphomas (22%), whereas only 1 of the 51 (2%) was picked up by conventional cytology (P ¼ .002). Similarly, Quijano et al 13 demonstrated that flow cytometry was able to identify leptomeningeal involvement by aggressive B-cell lymphoma in 27 of 123 patients (22%), whereas cytology was positive in only 7 of those 27 cases (26%). Bromberg et al 8 expanded their analysis to also include patients with a known myeloid malignancy. The sensitivity of flow cytometry in the detection of leptomeningeal disease was 2 to 3 times greater than that of cytology alone, and nearly 50% of leptomeningeal involvement was diagnosed by flow cytometry in the absence of positive cytology.
Although most of the published studies comparing cytology and flow cytometry in the detection of CNS lymphoma focused on the patient group with either history of lymphoma or high clinical suspicion for CNS lymphoma, our study is the largest, to our knowledge, to include a patient population lacking a history or firm clinical suspicion. Flow cytometry has become a routine ancillary tool for the clinicians in the workup of any patient with altered mental status at our hospital. We captured all flow cytometry requests from clinicians where a lymphoma screen had been performed during 10 years and focused on the value of simultaneous cytology and flow cytometry in the patient group where clinical suspicion was low.
Of the 102 patients who had no history of lymphoma and no suspicious radiologic findings, all (100%) had negative CSF cytology samples, and none (0%) of those patients had a correspondingly positive flow cytometry. These results are in concordance with published data from Craig et al 14 and Roma et al, 15 who included flow cytometry results from patients with no history of hematolymphoid malignancy. Craig et al 14 found only 1.4% (1 of 71) of the CSF specimens from these patients to be positive for a malignancy by flow cytometry, and Roma et al 15 reported that only 1 of the 18 patients (6%) with no history had both positive cytology and flow cytometry. 14, 15 Given these findings, Figure 4 offers an algorithm of how to preferentially use flow cytometry in the diagnosis of CNS lymphoma. First, patient history needs to be considered. Certainly, a patient with a known history of lymphoma is at risk for CNS spread, and an immunosuppressed patient is at risk for developing primary CNS lymphoma. However, even in a patient with a history of lymphoma, who now presents with typical clinical and radiologic findings of a cerebrovascular accident, likely does not require flow cytometric studies of the CSF fluid. Second, imaging results need to be incorporated into the assessment. Although less than half of patients with secondary CNS lymphoma show radiologic findings of CNS involvement, patients with primary CNS lymphoma often have discrete lesions. 12, 16 In our study, patients with a positive result by flow cytometry or brain biopsy were more likely to have a lymphoma history and/or abnormal radiologic findings (P , .009). Third, only cytology needs to be sent as an initial test on patients where clinical suspicion is low, and then, subsequently, flow cytometry is sent if the pathologic result or the clinical picture evolves. In our study, flow cytometry on CSF samples of patients with negative radiologic findings, negative history of hematologic malignancy, and negative cytology did not add additional clinical information, and was an unnecessary test. In these cases, only when the cytology is interpreted as suspicious for hematologic malignancy will the flow cytometric analysis be more likely to be helpful as an adjunct test. 17 In our study, false-positive results by cytology did occur in 8 of the 373 patients (2%). None had a history of a hematologic malignancy. A positive cytologic result in patients where clinical suspicion is low should prompt a repeat cytology with submission of CSF for flow cytometry to corroborate the potential lymphoma diagnosis.
In our study, open brain biopsy identified an additional 14 of the 373 patients (4%) with lymphomatous involvement of the CNS that was not detected by either FCA or cytologic examination. Furthermore, despite the reported high sensitivity of combined flow cytometry and cytology in high-risk patients, the NPV was only 52% in our study of all patients when compared with open brain biopsy. Almost half of patients with a negative or insufficient flow cytometry and negative cytology results may actually have undetected CNS involvement. Including patients with a low probability of lymphomatous involvement caused a decrease in the overall disease prevalence in our patient population and thereby decreased the value of the test.
The most common disease found on false-negative, follow-up brain biopsy was diffuse large B-cell lymphoma. False-negative results by FCA or cytology may partially be attributed to the location of the lymphoma within the CNS. Whereas secondary CNS lymphoma more commonly involves the leptomeninges, primary CNS lymphoma may present as a parenchymal lesion not shedding malignant cells into the CSF. 3 Still, CSF involvement is common enough in primary CNS lymphomas that both FCA and cytology of CSF are recommended as part of routine workup in these patients. 18 False-negative results in our study may also have been increased because of the high percentage of specimens classified as too few cells for flow cytometry analysis before July 2008, when analysis was not run on samples with a cell count less than 0.1 3 10 6 . Some of these samples may have provided positive results if tested. Running every CSF sample for flow cytometry at our institution, regardless of the cell count, resulted in a greater proportion of specimens with classified as too few B cells for clonality studies or no B cells in sample. B cells are generally much less frequent in the CSF than are T cells, and, according to the study by Subira et al, 19 B cells could only be reliably detected by flow cytometry if there were more than 5/lL. This highlights flow cytometry as having limited utility in detecting minute B-cell populations, and it may not be particularly helpful for patients with low clinical suspicion of lymphomatous involvement and only few B cells in the CSF.
This study indicates that flow cytometry is useful in the detection of hematologic malignancy in the CSF in the appropriate clinical setting; however, false-negative results can occur even with flow cytometry. Concurrent flow cytometry and cytology specimens are appropriate when clinical history and imaging point to a possible hematologic malignancy, but a stepwise approach is acceptable when clinical suspicion is low.
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